

Northwestern University Institutional Biosafety Committee

Meeting Minutes

Date: 9/17/2025 11:00 AM

Called to Order: 11:00 AM

Adjourned: 12:29 PM

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference (either Zoom or Microsoft Teams, as Northwestern policy requires). A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

IBC Members

Please see the NIH Office of Science Policy Registration Management System for official Committee Members' roles.

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	Present
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	Present
Lucy Godley	Member	-
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	-
Sarah Kopp	Member	Present
Maciej Lesniak	Member	-
Stephen Levin	Member	Present
Liming Li	Member	-
Emma Liechty	Member	-
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	Present
Irina Shepotinovskaya	Member	Present
Suchitra Swaminathan	Member	-
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	Present
Robert Birkett	Alternate	-

Name	Committee Role	Attendance
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	Present
Alicia McLuckie	Alternate	-
Marina Zelivyanskaya	Alternate	Present
James Zewe	Alternate	Present
Michael Hantak	Administrator	Present
Iwona Spath	Administrator	Present

Registrations for Full-Committee Review

Research Group	Principal Investigator	Submission Type
Castellani Lab	Rudy Castellani	Initial Protocol
Chen (Xi) Lab	Xi (Dawn) Chen	Initial Protocol
Amendment for BIO20220112	Isabelle De Plaen	Amendment
Amendment/CR for BIO20220115	Leo Gordon	Amendment/CR
Amendment for BIO20220097	Seema Khan	Amendment
Koralnik Lab	Igor Koralnik	De Novo Review
Amendment/CR for BIO20220016	Thomas Meade	Amendment/CR
Amendment/CR for BIO20220075	Puneet Opal	Amendment/CR
Amendment for BIO20230122	Karla Satchell	Amendment
Amendment for BIO20230012	Ali Shilatifard	Amendment
Tan Lab	Bruce Kuang-Huay Tan	Initial Protocol
Tan (Xiaodong) Lab	Xiaodong Tan	Initial Protocol
Wang (Christine) Lab	Christine Wang	Initial Protocol
Amendment/CR for BIO20220139	Jeffrey Weiss	Amendment/CR
Yang Lab	Rendong Yang	De Novo Review
Yi Lab	Rui Yi	Initial Protocol

Approval of Previous Meeting Minutes

Previous Meeting Date: 8/20/25

Determination: Approve

Comments: Smith made a motion to approve the meeting minutes with minor modifications. Hummel seconded the motion. The Committee unanimously supported the motion.

Meeting Minutes

Review of Castellani Lab

Initial Protocol

Principal Investigator: Rudy Castellani

Submission ID: BIO20240143

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1

Containment Level: BSL-2+

Determination: Approve with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Chen (Xi) Lab

Initial Protocol

Principal Investigator: Xi (Dawn) Chen

Submission ID: BIO20240190

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Amendment for BIO20220112

Amendment

Principal Investigator: Isabella De Plaen

Submission ID: BIO20220112-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20220115

Amendment/CR

Principal Investigator: Leo Gordon

Submission ID: BIO20220115-AMCR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-4-c
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20220097

Amendment

Principal Investigator: Seema Khan

Submission ID: BIO20220097-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Koralnik Lab

De Novo Review

Principal Investigator: Igor Koralnik

Submission ID: BIO20250091

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-E
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-E-1
- Section III-F-4
- Section III-F-8

Containment Level: BSL-2+

Determination: Approve with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20220016

Amendment/CR

Principal Investigator: Thomas Meade

Submission ID: BIO20220016-AMCR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20220075

Amendment/CR

Principal Investigator: Puneet Opal

Submission ID: BIO20220075-AMCR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20230122

Amendment

Principal Investigator: Karla Satchell

Submission ID: BIO20250032

Applicable NIH Guidelines:

- Section III-F-8-C-I
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-2
- Section III-D

Containment Level: BSL-2+

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment for BIO20230012

Amendment

Principal Investigator: Ali Shilatifard

Submission ID: BIO20230012-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Tan Lab

Initial Protocol

Principal Investigator: Bruce Kuang-Huay Tan

Submission ID: BIO20240113

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Review of Tan (Xiaodong) Lab

Initial Protocol

Principal Investigator: Xiaodong Tan

Submission ID: BIO20250094

Applicable NIH Guidelines:

- Section III-F-2
- Section III-E-3
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Wang (Christine) Lab

Initial Protocol

Principal Investigator: Christine Wang

Submission ID: BIO20250027

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Amendment/CR for BIO20220139

Amendment/CR

Principal Investigator: Jeffrey Weiss

Submission ID: BIO20220139-AMCR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-E-1

Containment Level: BSL-3

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Yang Lab

De Novo Review

Principal Investigator: Redong Yang

Submission ID: BIO20250098

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-F-1
- Section III-D-1
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

Containment Level: BSL-2

Determination: Approve

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

Review of Yi Lab

Initial Protocol

Principal Investigator: Rui Yi

Submission ID: BIO20240111

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Determination: Approve with minor modifications

Comments: The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

Administratively-Approved Exempt Registrations and Amendments

Amendment for BIO20220140

Amendment

Principal Investigator: Ankit Bharat

Submission ID: BIO20220140-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-7
- Section III-E-3-a
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/13/25

Continuing Review for BIO20220083

Continuing Review

Principal Investigator: Qi Cao

Submission ID: BIO20220083-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3

Containment Level: BSL-2

Approval Date: 8/25/25

Continuing Review for BIO20220028

Continuing Review

Principal Investigator: Debabrata Chakravarti

Submission ID: BIO20220028-CR0001

Applicable NIH Guidelines:

- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/28/25

Continuing Review for BIO20240114

Continuing Review

Principal Investigator: Jonathan Chen

Submission ID: BIO20240114-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 9/3/25

Amendment for BIO20230087

Amendment

Principal Investigator: Shawn Davidson

Submission ID: BIO20230087-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/22/25

DeVries Lab

Initial Protocol

Principal Investigator: Steven DeVries

Submission ID: BIO20250031

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/28/25

Continuing Review for BIO20240126

Continuing Review

Principal Investigator: Vinayak Dravid

Submission ID: BIO20240126-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8

Containment Level: BSL-1

Approval Date: 8/25/25

Continuing Review for BIO20240065

Continuing Review

Principal Investigator: Juan Du

Submission ID: BIO20240065-CR0001

Applicable NIH Guidelines:

- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/19/25

Continuing Review for BIO20230063

Continuing Review

Principal Investigator: Lucy Godley

Submission ID: BIO20230063-CR0001

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/25/25

Continuing Review for BIO20240026

Continuing Review

Principal Investigator: Arun Gosain

Submission ID: BIO20240026-CR0002

Applicable NIH Guidelines:

- Section III-F-2
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 8/4/25

Amendment for BIO20250089

Amendment

Principal Investigator: Alan Hauser

Submission ID: BIO20250089-AM0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-F-8-C-VIII
- Section III-F-8
- Section III-F-6

Containment Level: BSL-2

Approval Date: 9/4/25

Continuing Review for BIO20220124

Continuing Review

Principal Investigator: Peng Ji

Submission ID: BIO20220124-CR0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/5/25

Continuing Review for BIO20240021

Continuing Review

Principal Investigator: Pinelopi Kapitsinou

Submission ID: BIO20240021-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/25/25

Continuing Review for BIO20240033

Continuing Review

Principal Investigator: Neil Kelleher

Submission ID: BIO20240033-CR0001

Applicable NIH Guidelines:

Containment Level: BSL-2

Approval Date: 9/8/25

Amendment for BIO20220042

Amendment

Principal Investigator: John Kessler

Submission ID: BIO20220042-AM0002

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/20/25

InQbation Shared Lab 37C

Initial Protocol

Principal Investigator: Sonia Kim

Submission ID: BIO20240177

Applicable NIH Guidelines:

- Section III-F
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/10/25

Continuing Review for BIO20220077

Continuing Review

Principal Investigator: Jhumku Kohtz

Submission ID: BIO20220077-CR0002

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-D-2-a
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/25/25

Continuing Review for BIO20220013

Continuing Review

Principal Investigator: Shannon Lauberth

Submission ID: BIO20220013-CR0002

Applicable NIH Guidelines:

- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/3/25

Continuing Review for BIO20240094

Continuing Review

Principal Investigator: Talia Lerner

Submission ID: BIO20240094-CR0001

Applicable NIH Guidelines:

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/5/25

Continuing Review for BIO20240066

Continuing Review

Principal Investigator: Wei Lu

Submission ID: BIO20240066-CR0001

Applicable NIH Guidelines:

- Section III-E
- Section III-F-1
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/19/25

Continuing Review for BIO20240106

Continuing Review

Principal Investigator: Johanna Melo-Cardenas

Submission ID: BIO20240106-CR0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

Containment Level: BSL-2+

Approval Date: 8/25/25

Amendment for BIO20220015

Amendment

Principal Investigator: Stephen Miller

Submission ID: BIO20220015-AM0003

Applicable NIH Guidelines:

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/28/25

Continuing Review for BIO20240144

Continuing Review

Principal Investigator: Alfonso Mondragon

Submission ID: BIO20240144-CR0001

Applicable NIH Guidelines:

Containment Level: NA

Approval Date: 9/5/25

Amendment for BIO20220005

Amendment

Principal Investigator: Magdalena Osburn

Submission ID: BIO20220005-AM0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-8

Containment Level: BSL-1

Approval Date: 9/4/25

Amendment for BIO20230057

Amendment

Principal Investigator: Han Peng

Submission ID: BIO20230057-AM0003

Applicable NIH Guidelines:

- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/29/25

Continuing Review for BIO20230065

Continuing Review

Principal Investigator: Minoli Perera

Submission ID: BIO20230065-CR0002

Applicable NIH Guidelines:

- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/5/25

Amendment for BIO20240041

Amendment

Principal Investigator: Susan Quaggin

Submission ID: BIO20240041-AM0001

Applicable NIH Guidelines:

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/3/25

Continuing Review for BIO20240115

Continuing Review

Principal Investigator: Anne Rowley

Submission ID: BIO20240115-CR0001

Applicable NIH Guidelines:

- Section III-F-2
- Section III-F
- Section III-F-8

Containment Level: BSL-2

Approval Date: 9/8/25

Continuing Review for BIO20240003

Continuing Review

Principal Investigator: Hank Seifert

Submission ID: BIO20240003-CR0001

Applicable NIH Guidelines:

- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-F-4
- Section III-F-8

Containment Level: BSL-2

Approval Date: 8/28/25

Other Agenda Items

Description: Zhao (Youyang) Lab Compliance Update

Related Projects: BIO20240038

Notes: The Zhao (Youyang) Lab has complied with the IBC determination following recent non-compliance determination.

Description: Conflict of Interest Policy

Related Projects:

Notes: The policy had been provided to the Committee two days prior to the meeting.

Foreman provided a summary of the policy.

A motion was made by a Committee member to approve the policy.

Another Committee member seconded the motion.

The Committee unanimously supported the motion.

Description: HGT Termination protocol, 2015-0032, was submitted to the IBC. Designated reviewers approved the termination.

Related Projects: NSIS Registration ID: 2015-0032

Notes: The Primary Reviewer provided a summary of the submission to the Committee.

The Primary Reviewer made a motion to approve the termination.

The Committee unanimously supported the motion.